Free Trial
→ WATCH THIS BEFORE DECEMBER 8th!! (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grab Holdings Limited stock logo
GRAB
Grab
$3.08
-1.3%		$3.36
$2.74
▼
$6.60
$12.62B0.9177.17 million shs64.37 million shs
ThredUp Inc. stock logo
TDUP
ThredUp
$2.17
+1.9%		$3.19
$2.09
▼
$10.00
$284.99M2.112.06 million shs1.29 million shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.44
-0.7%		$0.50
$0.31
▼
$0.84
$106.50M1.05245,345 shs239,377 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grab Holdings Limited stock logo
GRAB
Grab
0.00%-1.60%-9.94%-21.03%-47.80%
ThredUp Inc. stock logo
TDUP
ThredUp
0.00%-3.56%-18.73%-69.13%-75.78%
Vaxart, Inc. stock logo
VXRT
Vaxart
0.00%-3.93%-11.27%-31.72%+15.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grab Holdings Limited stock logo
GRAB
Grab
$3.08
-1.3%		$3.36
$2.74
▼
$6.60
$12.62B0.9177.17 million shs64.37 million shs
ThredUp Inc. stock logo
TDUP
ThredUp
$2.17
+1.9%		$3.19
$2.09
▼
$10.00
$284.99M2.112.06 million shs1.29 million shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.44
-0.7%		$0.50
$0.31
▼
$0.84
$106.50M1.05245,345 shs239,377 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grab Holdings Limited stock logo
GRAB
Grab
0.00%-1.60%-9.94%-21.03%-47.80%
ThredUp Inc. stock logo
TDUP
ThredUp
0.00%-3.56%-18.73%-69.13%-75.78%
Vaxart, Inc. stock logo
VXRT
Vaxart
0.00%-3.93%-11.27%-31.72%+15.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grab Holdings Limited stock logo
GRAB
Grab
2.83
Moderate Buy$6.1198.21% Upside
ThredUp Inc. stock logo
TDUP
ThredUp
2.60
Moderate Buy$6.55201.84% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest GRAB, VXRT, and TDUP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
Grab Holdings Limited stock logo
GRAB
Grab
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/21/2026
ThredUp Inc. stock logo
TDUP
ThredUp
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/16/2026
Grab Holdings Limited stock logo
GRAB
Grab
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$7.00
8/17/2026
Grab Holdings Limited stock logo
GRAB
Grab
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-) ➝ Sell (D+)
8/6/2026
ThredUp Inc. stock logo
TDUP
ThredUp
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$6.50
8/6/2026
ThredUp Inc. stock logo
TDUP
ThredUp
Telsey Advisory Group logo
Telsey Advisory Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$7.00 ➝ $6.00
8/4/2026
Grab Holdings Limited stock logo
GRAB
Grab
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/3/2026
Grab Holdings Limited stock logo
GRAB
Grab
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
7/9/2026
Grab Holdings Limited stock logo
GRAB
Grab
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$7.00 ➝ $5.00
7/9/2026
Vaxart, Inc. stock logo
VXRT
Vaxart
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grab Holdings Limited stock logo
GRAB
Grab
$3.37B3.75$0.11 per share28.36$1.65 per share1.87
ThredUp Inc. stock logo
TDUP
ThredUp
$310.81M0.92N/AN/A$0.47 per share4.62
Vaxart, Inc. stock logo
VXRT
Vaxart
$237.26M0.45$0.10 per share4.27$0.37 per share1.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grab Holdings Limited stock logo
GRAB
Grab
$268M$0.0651.3423.690.8115.97%8.83%4.92%11/3/2026 (Estimated)
ThredUp Inc. stock logo
TDUP
ThredUp
-$20.21M-$0.17N/AN/AN/A-6.65%-37.30%-13.03%11/2/2026 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
$16.33M$0.162.73N/AN/A15.88%53.04%20.85%11/12/2026 (Estimated)

Latest GRAB, VXRT, and TDUP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.12-$0.06+$0.06-$0.06$26.21 million$27.19 million
8/5/2026Q2 2026
ThredUp Inc. stock logo
TDUP
ThredUp
-$0.0298-$0.05-$0.0202-$0.05$90.34 million$90.77 million
8/4/2026Q2 2026
Grab Holdings Limited stock logo
GRAB
Grab
$0.0495$0.06+$0.0105$0.06$994.97 million$997.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Grab Holdings Limited stock logo
GRAB
Grab
N/AN/AN/AN/AN/A
ThredUp Inc. stock logo
TDUP
ThredUp
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grab Holdings Limited stock logo
GRAB
Grab
0.06
1.52
1.51
ThredUp Inc. stock logo
TDUP
ThredUp
0.29
0.99
0.99
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
1.60
1.60

Institutional Ownership

CompanyInstitutional Ownership
Grab Holdings Limited stock logo
GRAB
Grab
55.52%
ThredUp Inc. stock logo
TDUP
ThredUp
89.08%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Grab Holdings Limited stock logo
GRAB
Grab
3.60%
ThredUp Inc. stock logo
TDUP
ThredUp
23.10%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grab Holdings Limited stock logo
GRAB
Grab
12,0124.10 billion3.95 billionOptionable
ThredUp Inc. stock logo
TDUP
ThredUp
2,132131.33 million101.00 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120243.70 million236.88 millionNo Data

Recent News About These Companies

Vaxart (OTCMKTS:VXRT) Share Price Breaks Below 200-Day Moving Average - Here's Why
October 1 at 3:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072512
Vaxart (OTCMKTS:VXRT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041425
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-vaxart-highlights-oral-vaccine-platform-covid-trial-progress-at-hc-wainwright-conference-2026-09-15/
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-present-h-c-wainwright-120000773.html
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357576/25416/en/vaxart-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology
August 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-secures-european-patent-covering-213754366.html
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351686/25416/en/vaxart-expands-intellectual-property-portfolio-with-european-patent-protecting-proprietary-norovirus-vaccine-technology.html
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-inc-vxrt-q2-2026-010727416.html
Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding
August 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4629637-vaxart-outlines-phase-iib-covidminus-19-top-line-data-in-first-half-of-2027-backed-by-barda
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933620-vaxart-inc-vxrt-q2-2026-earnings-call-transcript
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaxart-provides-business-update-and-reports-second-quarter-2026-financial-results-1036422626
Vaxart Q2 2026 earnings preview
August 5, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/vaxart-q2-2026-earnings-preview/ar-AA29sE4e
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-host-stockholder-fireside-chat-120000165.html
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3335990/25416/en/vaxart-to-host-stockholder-fireside-chat-on-august-7-at-4-30-p-m-et.html
Vaxart to Participate in BTIG Biotechnology Conference 2026
July 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-participate-btig-biotechnology-conference-120000945.html
Vaxart to Participate in BTIG Biotechnology Conference 2026
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330405/25416/en/vaxart-to-participate-in-btig-biotechnology-conference-2026.html
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-announces-results-annual-meeting-200500981.html
Vaxart Announces Results of Annual Meeting of Stockholders
July 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/17/3329278/25416/en/vaxart-announces-results-of-annual-meeting-of-stockholders.html
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
July 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-reports-topline-12-month-200100867.html
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
July 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/06/3322727/25416/en/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-safety-cohort-of-the-phase-2b-clinical-trial-of-its-oral-pill-covid-19-vaccine.html
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
July 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vaxart-enters-cooperation-agreement-stockholder-200000571.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Grab stock logo

Grab NASDAQ:GRAB

$3.08 -0.04 (-1.28%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$3.10 +0.02 (+0.49%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. The company offers its Grab ecosystem, a single platform with superapps for driver- and merchant-partners and consumers, that allows access to mobility, delivery, digital financial services, and enterprise sector offerings. Grab Holdings Limited is headquartered in Singapore.

ThredUp stock logo

ThredUp NASDAQ:TDUP

$2.17 +0.04 (+1.88%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.19 +0.02 (+0.78%)
As of 10/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.

Vaxart stock logo

Vaxart OTCMKTS:VXRT

$0.44 0.00 (-0.68%)
As of 10/2/2026 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas